AETNA BETTER HEALTH® Coverage Policy/Guideline					
Name:	Tracleer		Page:	1 of 4	
Effective Date: 12/21/2023			Last Review Date:	11/2023	
Applico	⊠Illinois	□Florida	🗆 Florida Kids		
Applies to:	□New Jersey	□Maryland	□Michigan		
10.	🗆 Pennsylvania Kids	□Virginia	□Kentucky PRMD		

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Tracleer under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1):

- A. In adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH, PAH associated with connective tissue diseases, and PAH associated with congenital heart disease with leftto-right shunts.
- B. In pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Tracleer (bosentan) 62.5 mg tablets Tracleer (bosentan) 125mg mg tablets Tracleer 32 mg tablets for suspension

Policy/Guideline:

Prescriber Specialty


This medication must be prescribed by or in consultation with a pulmonologist or cardiologist.

Criteria for Initial Approval:

Pulmonary Arterial Hypertension (PAH)

Authorization of 12 months may be granted for treatment of PAH when ALL of the following criteria are met:

- A. Member has PAH defined as WHO Group 1 class of pulmonary hypertension (refer to Appendix).
- B. PAH was confirmed by either criterion (1) or criterion (2) below:
 - 1. Pretreatment right heart catheterization with all of the following results:



□Kentucky PRMD

i. mPAP > 20 mmHg

□ Pennsylvania Kids

- ii. PCWP ≤ 15 mmHg
- iii. Pulmonary vascular resistance (PVR) \geq 3 Wood units in adult patients or pulmonary vascular resistance index (PVRI) \geq 3 Wood units x m2 in pediatric patients

□Virginia

- 2. For infants less than one year of age, PAH was confirmed by Doppler echocardiogram if right heart catheterization cannot be performed.
- C. Requests for generic Tracleer (bosentan) 62.5 mg or 125 mg tablets: Patient is unable to take the preferred brand Tracleer 62.5 or 125 mg tablets for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication.

Criteria for Continuation of Therapy:

Authorization of 12 months may be granted for members with an indication listed in criteria for initial approval who are currently receiving the requested medication through a paid pharmacy or medical benefit, and who are experiencing benefit from therapy as evidenced by disease stability or disease improvement.

Appendix

WHO Classification of Pulmonary Hypertension 1 PAH

- 1.1 Idiopathic (PAH)
- 1.2 Heritable PAH
- 1.3 Drug- and toxin-induced PAH
- 1.4. PAH associated with:
 - 1.4.1 Connective tissue diseases
 - 1.4.2 HIV infection
 - 1.4.3 Portal hypertension
 - 1.4.4 Congenital heart diseases
 - 1.4.5 Schistosomiasis
- 1.5 PAH long-term responders to calcium channel blockers
- 1.6 PAH with overt features of venous/capillaries (PVOD/PCH) involvement
- 1.7 Persistent PH of the newborn syndrome

2 PH due to left heart disease

- 2.1 PH due to heart failure with preserved LVEF
- 2.2 PH due to heart failure with reduced LVEF
- 2.3 Valvular heart disease
- 2.4 Congenital/acquired cardiovascular conditions leading to post-capillary PH



AETNA BETTER HEALTH®

Coverage Policy/Guideline

Name:	Tracleer		Page:	3 of 4
Effective Date:12/21/2023Last Review Date:11/2023				
Applies to:	⊠Illinois	□Florida	🗆 Florida Kids	
	□New Jersey	□Maryland	□Michigan	
	🗆 Pennsylvania Kids	□Virginia	□Kentucky PRMD	

3 PH due to lung diseases and/or hypoxia

- 3.1 Obstructive lung disease
- 3.2 Restrictive lung disease
- 3.3 Other lung disease with mixed restrictive/obstructive pattern
- 3.4 Hypoxia without lung disease
- 3.5 Developmental lung disorders

4 PH due to pulmonary artery obstruction

- 4.1 Chronic thromboembolic PH
- 4.2 Other pulmonary artery obstructions
 - 4.2.1 Sarcoma (high or intermediate grade) or angiosarcoma
 - 4.2.2 Other malignant tumors Renal carcinoma Uterine carcinoma Germ cell tumours of the testis Other tumours
 - 4.2.3 Non-malignant tumours Uterine leiomyoma
 - 4.2.4 Arteritis without connective tissue disease
 - 4.2.5 Congenital pulmonary artery stenosis
 - 4.2.6 Parasites
 - Hydatidosis

5 PH with unclear and/or multifactorial mechanisms

5.1 Hematologic disorders: Chronic hemolytic anemia, myeloproliferative disorders 5.2 Systemic and metabolic disorders: Pulmonary Langerhans cell histiocytosis, Gaucher disease, glycogen storage disease, neurofibromatosis, sarcoidosis


5.3 Others: chronic renal failure with or without hemodialysis, fibrosing mediastinitis 5.4 Complex congenital heart disease

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit:

- Tracleer 125 mg tablets: 60 per 30 days
- Tracleer 62.5mg tablets: 60 per 30 days
- Tracleer 32 mg tablets: 112 per 28 days



References:

- 1. Tracleer [package insert]. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; July 2022.
- 2. Bosentan [package insert]. Baltimore, MD: Lupin Pharmaceuticals, Inc; January 2023.
- 3. Chin KM, Rubin LJ. Pulmonary arterial hypertension. *J Am Coll Cardiol*. 2008;51(16):1527-1538.
- 4. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *J Am Coll Cardiol.* 2009;53(17):1573-1619.
- 5. Badesch DB, Champion HC, Gomez-Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;54:S55-S66.
- 6. Rubin LJ. American College of Chest Physicians. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest*. 2004;126(1 Suppl):7S-10S.
- 7. Barst RJ, Gibbs SR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;54:S78-S84.
- 8. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults. CHEST guideline and expert panel report. *Chest*. 2014;46(2):449-475.
- 9. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. *Circulation*. 2015;132(21):2037-99.
- 10. Klinger, JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guidelines and Expert Panel Report. *Chest*. 2019:155(3): 565-586.
- 11. Galie N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. *Eur Respir J.* 2019; 53: 1802148; DOI: 10.1183/13993003.02148-2018. Published 24 January 2019.
- 12. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J.* 2019;53:1801913; doi:10.1183/13993003.01913-2018.